title: Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
authors.forename: Helene F S
authors.initials: HF
authors.lastname: Negaard
authors.forename: Anette L
authors.initials: AL
authors.lastname: Eilertsen
authors.forename: Anders
authors.initials: A
authors.lastname: Dahm
authors.forename: Per O
authors.initials: PO
authors.lastname: Iversen
authors.forename: Bjørn
authors.initials: B
authors.lastname: Østenstad
authors.forename: Per M
authors.initials: PM
authors.lastname: Sandset
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor